{"id":"NCT01741545","sponsor":"Bristol-Myers Squibb","briefTitle":"Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia","officialTitle":"A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Naïve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03-31","primaryCompletion":"2015-01-31","completion":"2015-01-31","firstPosted":"2012-12-05","resultsPosted":"2019-06-24","lastUpdate":"2020-08-11"},"enrollment":71,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus"],"interventions":[{"type":"BIOLOGICAL","name":"Pegylated-Interferon-lambda","otherNames":["pegIFNλ","BMS-914143"]},{"type":"DRUG","name":"Ribavirin","otherNames":[]},{"type":"DRUG","name":"Daclatasvir","otherNames":["BMS-790052"]}],"arms":[{"label":"Cohort A: Genotype-2,-3 (Lambda/RBV/DCV)","type":"EXPERIMENTAL"},{"label":"Cohort B: Genotype-1b,-4 (Lambda/RBV/DCV)","type":"EXPERIMENTAL"}],"summary":"The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA \\< LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3","primaryOutcome":{"measure":"Percentage of Participants Who Achieved Sustained Virologic Response (SVR12) at Follow-Up Week 12","timeFrame":"Follow-up Week 12","effectByArm":[{"arm":"Cohort A","deltaMin":91.7,"sd":null},{"arm":"Cohort B","deltaMin":89.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":32,"countries":["United States","Australia","France","Italy","Netherlands","Romania","Russia","Spain"]},"refs":{"pmids":[],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Insomnia","Asthenia","Fatigue","Nausea","Headache"]}}